ProCE Banner Activity

KEYNOTE-029 Expansion Cohort: Pembrolizumab + Ipilimumab Safe, Active in Advanced Melanoma

Slideset Download
Conference Coverage
Pembrolizumab plus ipilimumab appear to be well tolerated and produced robust, durable responses in patients with advanced melanoma.

Released: June 14, 2016

Expiration: June 13, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals